Funding for this research was provided by:
BioCryst Pharmaceuticals, Inc.
Received: 13 April 2021
Accepted: 16 September 2021
First Online: 9 October 2021
: Institutional approval was not sought as patient data were anonymized and all patients provided written consent for their information to be published.
: All patients provided written informed consent for publication.
: RGG is a clinical research investigator for BioCryst, Takeda, KalVista, CSL Behring, and Pharming; has accepted speaker fees for BioCryst, Pharming, Takeda, and CSL Behring; and has accepted advisory board and consulting fees from BioCryst, Takeda, CSL Behring, and Pharming. MW is a clinical research coordinator for BioCryst, KalVista, and Takeda; and has accepted advisory board and consulting fees from BioCryst.